EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1

Xin Li iD, Hui Li iD, Ming-Ming Shao, Jinbai Miao, Yili Fu iD, Bin Hu

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.14989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Xin Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Chaoyang Hospital, Beijing, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung adenocarcinoma (LUAD) is the leading cause of death among cancer diseases. The tumorigenic functions of AHNAK2 in LUAD have attracted more attention in recent years, while there are few studies which have reported its high molecular weight.

Methods

The mRNA‐seq data of AHNAK2 and corresponding clinical data from UCSC Xena and GEO was analyzed. LUAD cell lines were transfected with sh‐NC and sh‐AHNAK2, and cell proliferation, migration and invasion were then detected by in vitro experiments. We performed RNA sequencing and mass spectrometry analysis to explore the downstream mechanism and interacting proteins of AHNAK2. Finally, western blot, cell cycle analysis and CO‐IP were used to confirm our assumptions regarding previous experiments.

Results

Our study revealed that AHNAK2 expression was significantly higher in tumors than in normal lung tissues and higher AHNAK2 expression led to a poor prognosis, especially in patients with advanced tumors. AHNAK2 suppression via shRNA reduced the LUAD cell lines proliferation, migration and invasion and induced significant changes in DNA replication, NF‐kappa B signaling pathway and cell cycle. AHNAK2 knockdown also caused G1/S phase cell cycle arrest, which could be attributed to the interaction of AHNAK2 and RUVBL1. In addition, the results from gene set enrichment analysis (GSEA) and RNA sequencing suggested that AHNAK2 probably plays a part in the mitotic cell cycle.

Conclusion

AHNAK2 promotes proliferation, migration and invasion in LUAD and regulates the cell cycle via the interaction with RUVBL1. More studies of AHNAK2 are still needed to reveal its upstream mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsHumansATPases Associated with Diverse Cellular ActivitiesCarrier ProteinsCell CycleCell Line, TumorCell MovementCell ProliferationDNA HelicasesDown-RegulationMembrane ProteinsNeoplasm Proteins

Stichwörter der Autor:innen

AHNAK2LUADRUVBL1cell cycle

Substanzen

ATPases Associated with Diverse Cellular ActivitiesCarrier ProteinsDNA HelicasesRUVBL1 protein, humanAHNAK protein, humanMembrane ProteinsNeoplasm Proteins

Autor:innen und Institutionen

  • Beijing Chaoyang Hospital, Beijing, China.
  • Thoracic Surgery, Beijing Chao-yang Hospital, Beijing, China.
  • Beijing Chao-Yang Hospital Capital Medical University, Beijing, China.
  • Department of Thoracic Surgery, Beijing Chao-Yang Hospital Affiliated Capital Medical University, Beijing, China.

ORCID-Profile: Xin Li, Hui Li, Yili Fu

Zitieren

APA

Li, X., Li, H., Shao, M. M., Miao, J., Fu, Y., & Hu, B. (2023). Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1. Thoracic Cancer. https://doi.org/10.1111/1759-7714.14989

Vancouver

Li X, Li H, Shao MM, Miao J, Fu Y, Hu B. Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1. Thoracic Cancer. 2023. doi:10.1111/1759-7714.14989

BibTeX
@article{Li2023,
  author = {Li, Xin and Li, Hui and Shao, Ming-Ming and Miao, Jinbai and Fu, Yili and Hu, Bin},
  title = {Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.14989}
}
Kostenlos starten →